DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
The generic ingredient in XOFLUZA is baloxavir marboxil. Two suppliers are listed for this compound. Additional details are available on the baloxavir marboxil profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 214410
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||FOR SUSPENSION;ORAL||Strength||2MG/ML|
|Approval Date:||Nov 23, 2020||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Oct 24, 2023|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||⤷ Free Forever Trial||Patent Expiration:||Apr 27, 2036||Product Flag?||Substance Flag?||Y||Delist Request?|
|Patent:||⤷ Free Forever Trial||Patent Expiration:||Apr 27, 2036||Product Flag?||Substance Flag?||Delist Request?|
|Patented Use:||METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA|
Complete Access Available with Subscription